Medical supply giant Medline has officially crossed the public markets threshold, capping months of anticipation with one of the largest initial public offerings in years.
It’s also an IPO that – in at least some ways – underscores the scale, ambition and financial muscle of a company with ties to the home medical equipment (HME) sector.
On Dec. 16, Medline announced the pricing of its upsized IPO. By Dec. 17, headlines across the health care news landscape highlighted Medline confirming a raise of $6.26 billion by selling more than 216 million shares at $29 apiece.
The offering values the company at more than $50 billion, making it the biggest IPO of the year and one of the largest in recent U.S. market history. Medline will begin trading under the Nasdaq stock ticker “MDLN.”
The milestone follows Medline’s September signals that it was targeting a roughly $5 billion IPO, a move that immediately caught the attention of HME executives and investors alike. At the time, the company framed the public offering as a way to strengthen its balance sheet, reduce debt and create flexibility for future growth, including investments across its sprawling distribution, manufacturing and technology operations.
The final numbers suggest demand far exceeded those early expectations.
Medline, a privately held company for decades before being acquired by private equity firms in 2021, operates at a scale few in the medical supply ecosystem can match. The company distributes more than 300,000 products and serves providers across acute care, post-acute, home health and HME channels.
While not a pure-play HME supplier, Medline’s footprint in respiratory, wound care, mobility and disposable medical supplies makes it a critical partner – and occasional competitor – for many businesses in the space.
A publicly traded Medline will now face heightened pressure to deliver consistent growth and operational efficiency, potentially accelerating investments in automation, private-label products and supply chain optimization.
What’s more, the IPO signals investor confidence in health care supply chains after years of pandemic-driven disruption and margin pressure. Medline’s ability to command a valuation north of $50 billion suggests investors and others see long-term opportunity in scale, logistics and data-driven purchasing power – all themes increasingly shaping the HME market, too.
